Q3 EPS Forecast for Medexus Pharmaceuticals Cut by Analyst

Medexus Pharmaceuticals Inc. (TSE:MDP) – Investment analysts at Raymond James decreased their Q3 2026 earnings per share (EPS) estimates for shares of Medexus Pharmaceuticals in a report issued on Tuesday, January 7th. Raymond James analyst M. Freeman now expects that the company will post earnings per share of $0.22 for the quarter, down from their previous forecast of $0.24. Raymond James has a “Strong-Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2026 earnings at $0.23 EPS, FY2026 earnings at $0.89 EPS, FY2027 earnings at $0.88 EPS, FY2028 earnings at $0.80 EPS and FY2029 earnings at $0.77 EPS.

A number of other equities research analysts also recently weighed in on MDP. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Leede Financial set a C$8.25 price objective on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a report on Monday, September 30th. Two investment analysts have rated the stock with a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, Medexus Pharmaceuticals has a consensus rating of “Strong Buy” and an average price target of C$5.25.

Medexus Pharmaceuticals Stock Up 13.1 %

Shares of Medexus Pharmaceuticals stock opened at C$4.07 on Thursday. The stock has a market capitalization of C$99.84 million, a price-to-earnings ratio of 81.40 and a beta of 1.96. Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$4.07. The company has a 50-day simple moving average of C$2.74 and a two-hundred day simple moving average of C$2.52.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.